[
  {
    "ts": null,
    "headline": "How Investors Are Reacting To Danaher (DHR) Upbeat 2025 Outlook And Growing Synthetic Biology Ambitions",
    "summary": "In early January 2026, Danaher announced ahead of the J.P. Morgan Healthcare Conference that it expects fourth-quarter 2025 revenue and full-year non-GAAP adjusted diluted EPS to finish toward the upper end of prior guidance, backed by solid bioprocessing, life sciences, and diagnostics performance. A separate update from Danaher company Integrated DNA Technologies highlighted a new collaboration with Ansa Biotechnologies, expanding access to longer, more complex DNA constructs and...",
    "url": "https://finnhub.io/api/news?id=b568dacc34c1c001b94c9451da04bb35e199238a3a3fadc12ea1f3748ac0332c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768417757,
      "headline": "How Investors Are Reacting To Danaher (DHR) Upbeat 2025 Outlook And Growing Synthetic Biology Ambitions",
      "id": 138114761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "In early January 2026, Danaher announced ahead of the J.P. Morgan Healthcare Conference that it expects fourth-quarter 2025 revenue and full-year non-GAAP adjusted diluted EPS to finish toward the upper end of prior guidance, backed by solid bioprocessing, life sciences, and diagnostics performance. A separate update from Danaher company Integrated DNA Technologies highlighted a new collaboration with Ansa Biotechnologies, expanding access to longer, more complex DNA constructs and...",
      "url": "https://finnhub.io/api/news?id=b568dacc34c1c001b94c9451da04bb35e199238a3a3fadc12ea1f3748ac0332c"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Danaher positioned to improve patient diagnostics",
    "summary": "Danaher anticipates a strong 2026 due to its diagnostic portfolio being in highly attractive areas such as molecular testing, pathology and blood gas, and in core lab.",
    "url": "https://finnhub.io/api/news?id=cd544a9a45286781caedef386bdf459ec0d33119a84103a02231f6bebc8e11e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768416268,
      "headline": "JPM26: Danaher positioned to improve patient diagnostics",
      "id": 138114762,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Danaher anticipates a strong 2026 due to its diagnostic portfolio being in highly attractive areas such as molecular testing, pathology and blood gas, and in core lab.",
      "url": "https://finnhub.io/api/news?id=cd544a9a45286781caedef386bdf459ec0d33119a84103a02231f6bebc8e11e6"
    }
  },
  {
    "ts": null,
    "headline": "Integrated DNA Technologies Expands Synthetic Biology Portfolio with Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA Products",
    "summary": "SUNNYVALE, Calif. & EMERYVILLE, Calif., January 14, 2026--IDT and Ansa are joining forces to empower customers with sequence-perfect constructs up to 50 kb, expanding IDT's synthetic biology portfolio.",
    "url": "https://finnhub.io/api/news?id=36ca5a8a096277cdcbf84b5790acde0cebe7bfaffb71266ce7f2a2e4800611c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768395900,
      "headline": "Integrated DNA Technologies Expands Synthetic Biology Portfolio with Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA Products",
      "id": 138111266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "SUNNYVALE, Calif. & EMERYVILLE, Calif., January 14, 2026--IDT and Ansa are joining forces to empower customers with sequence-perfect constructs up to 50 kb, expanding IDT's synthetic biology portfolio.",
      "url": "https://finnhub.io/api/news?id=36ca5a8a096277cdcbf84b5790acde0cebe7bfaffb71266ce7f2a2e4800611c2"
    }
  },
  {
    "ts": null,
    "headline": "Danaher (DHR) Rebounded on Accelerated Demand",
    "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its […]",
    "url": "https://finnhub.io/api/news?id=12478f0460ff03724476171997d9f9f2cd81b6ccae1e014eec199dac54af3b99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768395439,
      "headline": "Danaher (DHR) Rebounded on Accelerated Demand",
      "id": 138111267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its […]",
      "url": "https://finnhub.io/api/news?id=12478f0460ff03724476171997d9f9f2cd81b6ccae1e014eec199dac54af3b99"
    }
  }
]